PLUS THERAPEUTICS, Inc. - PSTV STOCK NEWS

Plus Therapeutics (PSTV) has reported positive interim results from its Phase 1 ReSPECT™-GBM clinical trial, focusing on the investigational drug Rhenium-186 NanoLiposome (186RNL) for recurrent glioblastoma (GBM). The study revealed it is well-tolerated with no dose-limiting toxicities. Patients receiving more than 100 Gy of radiation experienced a mean overall survival of 453.8 days. The trial has evaluated 22 patients over six years, and significant delivery parameters were noted, supporting further clinical investigations.

Plus Therapeutics, Inc. (PSTV) announced the granting of option awards to Dr. Norman LaFrance on November 11, 2021, as part of his induction as Chief Medical Officer. The awards include options to purchase up to 120,000 shares of common stock, vesting over four years with specific conditions related to Dr. LaFrance's continued service. This move aims to align his interests with those of the shareholders. The options were granted outside of the company's 2020 Incentive Plan but follow similar terms. Plus Therapeutics is focused on innovative treatments for cancer.

Plus Therapeutics (NASDAQ: PSTV) has received Fast Track designation from the FDA for its Rhenium-186 NanoLiposome (¹⁸⁶RNL) aimed at treating leptomeningeal metastases (LM). This condition affects 5% of cancer patients, often resulting in severe health complications. The company expects to begin patient accrual for the ReSPECT-LM Phase 1 clinical trial in Q4 2021. The Fast Track status allows for accelerated communication with the FDA, potentially speeding up the development and approval process.

Plus Therapeutics (PSTV) announced a webinar on November 18, 2021, from 4:00 to 5:00 p.m. ET, discussing the ReSPECT-GBM trial data. Key opinion leaders will present findings on the safety and efficacy of Rhenium-186 NanoLiposome in treating recurrent glioblastoma. Speakers include Dr. Andrew J. Brenner, who will provide trial updates, and Dr. Toral Patel, who will discuss convection enhanced delivery in neurosurgery. The webinar allows for analyst and public Q&A. Data will also be presented at the Society for Neuro-Oncology Annual Meeting on November 19, 2021.

Plus Therapeutics (Nasdaq: PSTV) presented promising data on Rhenium-186 NanoLiposome (186RNL) at the ASTRO 2021 Annual Meeting, indicating its effectiveness in treating recurrent glioblastoma. The therapy demonstrated sustained, localized radiation treatment for over eight days, significantly reducing whole brain and body radiation exposure. Key findings include a mean radiation absorbed dose of 354.7 Gy to the tumor with minimal surrounding exposure. The data also supported the use of image monitoring for therapy delivery evaluation, highlighting the innovative delivery system of 186RNL.

Plus Therapeutics, Inc. (PSTV) reported its third-quarter financial results for 2021, highlighting significant advancements in its clinical trials, particularly the ReSPECT-GBM trial for recurrent glioblastoma. The company increased the trial dose by 40% without dose-limiting toxicities and received FDA clearance for its IND application for leptomeningeal metastases. Cash on hand rose to $21.3 million, while net loss was $3.7 million, reflecting increased R&D expenses. Plus Therapeutics plans to initiate further trials and strengthen its drug manufacturing capabilities in the upcoming months.

Plus Therapeutics (PSTV) announced FDA clearance for its Investigational New Drug (IND) application for Rhenium-186 NanoLiposome (186RNL), targeting leptomeningeal metastases (LM). Patient accrual for the Phase 1 dose escalation clinical trial, ReSPECT-LM, is expected to start in Q4 2021. The trial aims to assess the safety and efficacy of 186RNL, based on promising preclinical results showing marked tumor reduction and no significant toxicity in animal models. This represents a significant step towards innovative treatment options for patients with rare, difficult-to-treat cancers.

Plus Therapeutics (PSTV) will report its third quarter 2021 financial results on October 21, 2021, after market close. Management will host a conference call at 5:00 p.m. ET to discuss these results and provide a corporate update. The event can be accessed via live webcast, and a replay will be available on the company's website for 90 days. Plus Therapeutics focuses on developing targeted radiotherapeutics using a unique nanotechnology platform, aiming to treat rare cancers more effectively.

Plus Therapeutics (Nasdaq: PSTV) announced it will present interim data from its ReSPECT™ Phase 1 clinical trial of Rhenium-186 NanoLiposome (186RNL) for recurrent glioblastoma at the Society for Neuro-Oncology Annual Meeting, scheduled for November 19, 2021. The presentation will cover the safety and feasibility of this innovative treatment. Dr. Andrew Brenner, the principal investigator, will lead the session, highlighting potential advancements in oncology therapeutics aimed at improving patient outcomes.